Skip to main content
Application Note

CDK signaling- Investigate CDK4-6 inhibition in breast cancer cell lines with HTRF immunoassays

cdk-signaling

Cyclin-dependent kinases (CDKs) 4 & 6 play a key in breast cancer. Cyclin D1-CDK4/6 complexes are critical regulators of the cell cycle transition from the G1 to S phase. To proceed through these phases, a cell must pass a restrictive checkpoint, tightly regulated in this case by the retinoblastoma tumor suppressor protein (Rb). Palbociclib is a small molecule kinase inhibitor that blocks Cyclin D1-CDK4/6 mediated phosphorylation of the Rb protein to prevent E2F driven transcription of genes that commit the cell to DNA replication and cell division.

In this application note, you will learn:

  • The effect of palbociclib treatment in two breast cancer cell lines
  • How to monitor the amount of phospho-Rb and Cyclin D1 protein levels with HTRF®® immunoassays to examine the effect of CDK4/6 inhibition and Cyclin D1 regulation

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Resource

CDK signaling- Investigate CDK4-6 inhibition in breast cancer cell lines with HTRF immunoassays

Download Application Note